fig5

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance

Figure 5. Gene Expression Levels for Tyrosine Kinases in Leukemic Cells from Adult Patients with KMT2A/MLL-R+ AML vs. Other subsets of AML without KMT2A/MLL rearrangements. Probeset level normalized signal values from the archived data set GSE13159 were examined in these comparisons. The cluster figure displays the expression levels in KMT2A/MLL-R+ AML cells mean centered to the reference group (other AML subsets without KMT2A/MLL rearrangements) for log2-transformed fold change values (blue to red color indicates under-expression to over-expression respectively in KMT2A/MLL-R+ samples). Co-regulated probesets are organized and depicted by dendrograms for both probesets (rows) and patients (columns). Side-by-side comparison of 38 adult MLL-R+ AML cases with 504 other non-MLL-R+ adult AML cases resulted in 15 dysregulated probesets, of which 6 were upregulated in the adult KMT2A/MLL-R+ subset of cases. FGR_208438_s_at was the most significantly upregulated probeset (Fold Change = 2.46; P-value < 10-8) followed by HCK_208018_s_at (Fold Change = 2.1; P-value < 10-8) and TYK2_205546_s_at (Fold Change = 1.29; P-value = 0.0012) [Supplementary Table 10]. Cluster visualization of the mean centered expression values suggested co-regulation of CD33 with BTK, TYK2 and SYK (3 probesets).

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/